Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Randomized, Double-Blind, Placebo-Controlled and Delayed-Start Study of LY3314814 in Mild Alzheimer's Disease Dementia (The DAYBREAK Study)

Next Previous
Trial Profile

A Randomized, Double-Blind, Placebo-Controlled and Delayed-Start Study of LY3314814 in Mild Alzheimer's Disease Dementia (The DAYBREAK Study)

Status: Discontinued
Phase of Trial: Phase III

Latest Information Update: 01 Apr 2022

Price : $35 *
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Lanabecestat (Primary)
  • Indications Alzheimer's disease
  • Focus Therapeutic Use
  • Acronyms DAYBREAK; Daybreak Study; DAYBREAK-ALZ
  • Sponsors AstraZeneca; Eli Lilly and Company; Eli Lilly and Company (India) Pvt. Ltd

    • Most Recent Events

    • 31 Jul 2020 Results assessing the most common reasons for exclusion within sex in Lanabecestat studies AMARANTH and DAYBREAK-ALZ presented at the Alzheimer's Association International Conference 2020
    • 21 Jul 2020 According to an Eli Lilly and Company media release, data from this trial will be presented at the upcoming Alzheimers Association International Conference 2020 (AAIC 2020) which will be held virtually July 27-31, 2020
    • 25 Nov 2019 Results assessing whether lanabecestat slows the progression of AD compared with placebo using data from AMARANTH and DAYBREAK_ALZ trials published in the JAMA Neurology
Subscriber content

You need to be a logged in subscriber to view this content.

If your organization has a subscription then there are several options available to help you access AdisInsight, even while working remotely.

  • IP authentication when working within your organization’s network.
  • with username/password or try via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days.
  • Contact us at AsktheExpert.AdisInsight@springer.com for assistance.

If your organization does not have a subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Buy a PDF version of the profile.
  • Request a free trial
Legal
Back to top